Tolerance of the spinal cord to stereotactic radiosurgery

Insights from hemangioblastomas

Megan E Daly, Clara Y H Choi, Iris C. Gibbs, John R. Adler, Steven D. Chang, Robert E. Lieberson, Scott G. Soltys

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Purpose: To evaluate spinal cord dose-volume effects, we present a retrospective review of stereotactic radiosurgery (SRS) treatments for spinal cord hemangioblastomas. Methods and Materials: From November 2001 to July 2008, 27 spinal hemangioblastomas were treated in 19 patients with SRS. Seventeen tumors received a single fraction with a median dose of 20 Gy (range, 18-30 Gy). Ten lesions were treated using 18-25 Gy in two to three sessions. Cord volumes receiving 8, 10, 12, 14, 16, 18, 20, 22, and 24 Gy and dose to 10, 100, 250, 500, 1000, and 2000 mm 3 of cord were determined. Multisession treatments were converted to single-fraction biologically effective dose (SFBED). Results: Single-fraction median cord D max was 22.7 Gy (range, 17.8-30.9 Gy). Median V10 was 454 mm 3 (range, 226-3543 mm 3). Median dose to 500 mm 3 cord was 9.5 Gy (range, 5.3-22.5 Gy). Fractionated median SFBED 3 cord D max was 14.1 Gy 3 (range, 12.3-19.4 Gy 3). Potential toxicities included a Grade 2 unilateral foot drop 5 months after SRS and 2 cases of Grade 1 sensory deficits. The actuarial 3-year local tumor control estimate was 86%. Conclusions: Despite exceeding commonly cited spinal cord dose constraints, SRS for spinal hemangioblastomas is safe and effective. Consistent with animal experiments, these data support a partial-volume tolerance model for the human spinal cord. Because irradiated cord volumes were generally small, application of these data to other clinical scenarios should be made cautiously. Further prospective studies of spinal radiosurgery are needed.

Original languageEnglish (US)
Pages (from-to)213-220
Number of pages8
JournalInternational Journal of Radiation Oncology Biology Physics
Volume80
Issue number1
DOIs
StatePublished - May 1 2011
Externally publishedYes

Fingerprint

Hemangioblastoma
spinal cord
Radiosurgery
Spinal Cord
dosage
grade
tumors
Foot
Neoplasms
Prospective Studies
toxicity
lesions
animals
Therapeutics
estimates

Keywords

  • Hemangioblastoma
  • Radiosurgery
  • SBRT
  • Spinal
  • Spinal cord tolerance

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Tolerance of the spinal cord to stereotactic radiosurgery : Insights from hemangioblastomas. / Daly, Megan E; Choi, Clara Y H; Gibbs, Iris C.; Adler, John R.; Chang, Steven D.; Lieberson, Robert E.; Soltys, Scott G.

In: International Journal of Radiation Oncology Biology Physics, Vol. 80, No. 1, 01.05.2011, p. 213-220.

Research output: Contribution to journalArticle

Daly, Megan E ; Choi, Clara Y H ; Gibbs, Iris C. ; Adler, John R. ; Chang, Steven D. ; Lieberson, Robert E. ; Soltys, Scott G. / Tolerance of the spinal cord to stereotactic radiosurgery : Insights from hemangioblastomas. In: International Journal of Radiation Oncology Biology Physics. 2011 ; Vol. 80, No. 1. pp. 213-220.
@article{36dd3eef8c5f41528862500b641b6d51,
title = "Tolerance of the spinal cord to stereotactic radiosurgery: Insights from hemangioblastomas",
abstract = "Purpose: To evaluate spinal cord dose-volume effects, we present a retrospective review of stereotactic radiosurgery (SRS) treatments for spinal cord hemangioblastomas. Methods and Materials: From November 2001 to July 2008, 27 spinal hemangioblastomas were treated in 19 patients with SRS. Seventeen tumors received a single fraction with a median dose of 20 Gy (range, 18-30 Gy). Ten lesions were treated using 18-25 Gy in two to three sessions. Cord volumes receiving 8, 10, 12, 14, 16, 18, 20, 22, and 24 Gy and dose to 10, 100, 250, 500, 1000, and 2000 mm 3 of cord were determined. Multisession treatments were converted to single-fraction biologically effective dose (SFBED). Results: Single-fraction median cord D max was 22.7 Gy (range, 17.8-30.9 Gy). Median V10 was 454 mm 3 (range, 226-3543 mm 3). Median dose to 500 mm 3 cord was 9.5 Gy (range, 5.3-22.5 Gy). Fractionated median SFBED 3 cord D max was 14.1 Gy 3 (range, 12.3-19.4 Gy 3). Potential toxicities included a Grade 2 unilateral foot drop 5 months after SRS and 2 cases of Grade 1 sensory deficits. The actuarial 3-year local tumor control estimate was 86{\%}. Conclusions: Despite exceeding commonly cited spinal cord dose constraints, SRS for spinal hemangioblastomas is safe and effective. Consistent with animal experiments, these data support a partial-volume tolerance model for the human spinal cord. Because irradiated cord volumes were generally small, application of these data to other clinical scenarios should be made cautiously. Further prospective studies of spinal radiosurgery are needed.",
keywords = "Hemangioblastoma, Radiosurgery, SBRT, Spinal, Spinal cord tolerance",
author = "Daly, {Megan E} and Choi, {Clara Y H} and Gibbs, {Iris C.} and Adler, {John R.} and Chang, {Steven D.} and Lieberson, {Robert E.} and Soltys, {Scott G.}",
year = "2011",
month = "5",
day = "1",
doi = "10.1016/j.ijrobp.2010.01.040",
language = "English (US)",
volume = "80",
pages = "213--220",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Tolerance of the spinal cord to stereotactic radiosurgery

T2 - Insights from hemangioblastomas

AU - Daly, Megan E

AU - Choi, Clara Y H

AU - Gibbs, Iris C.

AU - Adler, John R.

AU - Chang, Steven D.

AU - Lieberson, Robert E.

AU - Soltys, Scott G.

PY - 2011/5/1

Y1 - 2011/5/1

N2 - Purpose: To evaluate spinal cord dose-volume effects, we present a retrospective review of stereotactic radiosurgery (SRS) treatments for spinal cord hemangioblastomas. Methods and Materials: From November 2001 to July 2008, 27 spinal hemangioblastomas were treated in 19 patients with SRS. Seventeen tumors received a single fraction with a median dose of 20 Gy (range, 18-30 Gy). Ten lesions were treated using 18-25 Gy in two to three sessions. Cord volumes receiving 8, 10, 12, 14, 16, 18, 20, 22, and 24 Gy and dose to 10, 100, 250, 500, 1000, and 2000 mm 3 of cord were determined. Multisession treatments were converted to single-fraction biologically effective dose (SFBED). Results: Single-fraction median cord D max was 22.7 Gy (range, 17.8-30.9 Gy). Median V10 was 454 mm 3 (range, 226-3543 mm 3). Median dose to 500 mm 3 cord was 9.5 Gy (range, 5.3-22.5 Gy). Fractionated median SFBED 3 cord D max was 14.1 Gy 3 (range, 12.3-19.4 Gy 3). Potential toxicities included a Grade 2 unilateral foot drop 5 months after SRS and 2 cases of Grade 1 sensory deficits. The actuarial 3-year local tumor control estimate was 86%. Conclusions: Despite exceeding commonly cited spinal cord dose constraints, SRS for spinal hemangioblastomas is safe and effective. Consistent with animal experiments, these data support a partial-volume tolerance model for the human spinal cord. Because irradiated cord volumes were generally small, application of these data to other clinical scenarios should be made cautiously. Further prospective studies of spinal radiosurgery are needed.

AB - Purpose: To evaluate spinal cord dose-volume effects, we present a retrospective review of stereotactic radiosurgery (SRS) treatments for spinal cord hemangioblastomas. Methods and Materials: From November 2001 to July 2008, 27 spinal hemangioblastomas were treated in 19 patients with SRS. Seventeen tumors received a single fraction with a median dose of 20 Gy (range, 18-30 Gy). Ten lesions were treated using 18-25 Gy in two to three sessions. Cord volumes receiving 8, 10, 12, 14, 16, 18, 20, 22, and 24 Gy and dose to 10, 100, 250, 500, 1000, and 2000 mm 3 of cord were determined. Multisession treatments were converted to single-fraction biologically effective dose (SFBED). Results: Single-fraction median cord D max was 22.7 Gy (range, 17.8-30.9 Gy). Median V10 was 454 mm 3 (range, 226-3543 mm 3). Median dose to 500 mm 3 cord was 9.5 Gy (range, 5.3-22.5 Gy). Fractionated median SFBED 3 cord D max was 14.1 Gy 3 (range, 12.3-19.4 Gy 3). Potential toxicities included a Grade 2 unilateral foot drop 5 months after SRS and 2 cases of Grade 1 sensory deficits. The actuarial 3-year local tumor control estimate was 86%. Conclusions: Despite exceeding commonly cited spinal cord dose constraints, SRS for spinal hemangioblastomas is safe and effective. Consistent with animal experiments, these data support a partial-volume tolerance model for the human spinal cord. Because irradiated cord volumes were generally small, application of these data to other clinical scenarios should be made cautiously. Further prospective studies of spinal radiosurgery are needed.

KW - Hemangioblastoma

KW - Radiosurgery

KW - SBRT

KW - Spinal

KW - Spinal cord tolerance

UR - http://www.scopus.com/inward/record.url?scp=79953874804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953874804&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2010.01.040

DO - 10.1016/j.ijrobp.2010.01.040

M3 - Article

VL - 80

SP - 213

EP - 220

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -